For decades, the pharmaceutical industry’s most familiar strategy for extending the commercial life of a successful medicine has been to make a new version of it: a different formulation, dosage, salt, delivery system or chemical cousin that can generate fresh patents and attract new investment. A commentary published in Nature Biotechnology argues that this familiar practice, known as product hopping, is entering a more ambitious phase. The authors examine the transition from cabozantinib to zanzalintinib and present it as a striking example of how apparently straightforward chemical changes can produce a new drug-development platform.
Cabozantinib is an orally administered tyrosine kinase inhibitor designed to interfere with signaling pathways that tumors use to grow, invade surrounding tissues and recruit blood vessels. Its molecular targets include vascular endothelial growth factor receptors, particularly VEGFR2, as well as MET and AXL, proteins associated with angiogenesis, metastatic behavior and resistance to therapy. By blocking these kinases, cabozantinib can disrupt both the cancer cell and the tumor microenvironment. The drug has become an established treatment in several oncology settings, including renal cell carcinoma and selected thyroid and liver cancers, making it a valuable starting point for further medicinal-chemistry innovation.
Zanzalintinib, also known as XL092 during its development, belongs to the same broad family of kinase inhibitors but is not simply cabozantinib under a new name. It is an investigational compound built around the idea that carefully selected structural adjustments can alter a molecule’s biological profile without abandoning the pharmacological logic that made its predecessor effective. The central scientific question is not whether the new molecule looks radically different, but whether small changes can tune properties such as target selectivity, tissue distribution, metabolic stability, dosing behavior and tolerability.
That distinction is crucial in kinase drug design. A compound can bind several enzymes with related structures, but the strength and duration of those interactions may vary significantly after even modest chemical editing. Changes to substituents, hydrogen-bonding groups, ring systems or the molecule’s three-dimensional shape can influence how tightly it fits into a kinase’s ATP-binding pocket. They can also affect how rapidly the liver metabolizes the compound, how it crosses cell membranes and how long therapeutically useful concentrations remain in the bloodstream. In oncology, where treatment may continue for months or years, these pharmacological details can determine whether a promising mechanism becomes a practical medicine.
The cabozantinib-to-zanzalintinib story therefore illustrates a form of molecular optimization that is more subtle than the discovery of an entirely new chemical class. Instead of starting from an empty research program, scientists can use an existing drug as a map of validated biology. The original medicine identifies pathways worth targeting, reveals clinically relevant exposure levels and provides information about toxicities and resistance. Researchers can then modify the structure to seek a different balance between potency and safety. The result may retain the parent drug’s therapeutic rationale while opening opportunities for new combinations, disease settings or treatment schedules.
The authors describe this approach as a new frontier in product hopping because the modifications can be chemically obvious in retrospect yet strategically important in practice. “Obvious” does not mean effortless. Medicinal chemistry often advances through hundreds or thousands of analogues, each differing by a small change, before one achieves the desired combination of activity, selectivity and drug-like behavior. A fluorine atom, an altered linker or a replacement ring can change a molecule’s electronic properties, shape and interaction with proteins. The challenge is to identify which apparently minor edits produce a meaningful clinical advantage rather than merely a cosmetic variation.
The commercial implications are substantial. A follow-on molecule based on an established drug can benefit from years of prior biological knowledge, manufacturing experience and clinical precedent. At the same time, it may create new intellectual-property positions and support a fresh development program as the original product approaches the limits of its patent life or market opportunity. For companies, this can reduce some of the uncertainty associated with discovering a medicine from scratch. For patients, the strategy could produce compounds that are easier to tolerate, more convenient to administer or better suited to combination therapy. But it also raises a longstanding question: when does a genuine therapeutic improvement become little more than a commercial extension of an existing product?
That question is especially important for targeted cancer medicines, because their clinical value depends on more than laboratory potency. A new kinase inhibitor must demonstrate that its altered profile translates into improved outcomes, manageable adverse effects or meaningful activity in patients whose tumors have stopped responding to earlier treatments. If zanzalintinib can offer a distinct balance of VEGFR, MET and TAM-family kinase activity, for example, its potential may lie not only in replacing cabozantinib but also in being paired with immunotherapies or other targeted agents. Such combinations require careful attention to overlapping toxicities, pharmacokinetic interactions and the biological consequences of simultaneously suppressing several signaling networks.
The case also highlights how modern drug development increasingly blurs the boundaries between innovation and refinement. Breakthroughs do not always arrive as entirely new molecular architectures. Sometimes they emerge from a disciplined re-examination of a known scaffold, guided by structural biology, computational modeling, pharmacology and clinical experience. The authors’ analysis suggests that the next generation of pharmaceutical competition may be shaped by these “obvious” modifications: changes that appear small on the page but can redirect a drug’s behavior inside the body. Whether that strategy delivers genuine progress will ultimately depend on evidence from clinical trials, not on chemical novelty alone.
Subject of Research: Product hopping and medicinal-chemistry optimization in the development of zanzalintinib from cabozantinib.
Article Title: From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping.
Article References: Strohbehn, G.W., Tu, S.S., Wang, X. et al. From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping. Nat Biotechnol 44, 1274–1279 (2026). https://doi.org/10.1038/s41587-026-03242-w
Image Credits: AI Generated
DOI: 10.1038/s41587-026-03242-w
Keywords: Cabozantinib, zanzalintinib, product hopping, medicinal chemistry, tyrosine kinase inhibitors, cancer therapeutics, drug development, pharmaceutical innovation.
